Kerendia patent expiration dat?

When Does Kerendia's Patent Expire?

Kerendia, also known as finerenone, is a medication used to treat patients with diabetic nephropathy with and without established cardiovascular disease [1]. Developed by Bayer and Janssen Pharmaceuticals, Kerendia has been the subject of significant interest due to its effectiveness in slowing the progression of kidney disease in patients with type 2 diabetes.

Why Is Patent Expiration Important for Kerendia?

Patent expiration is crucial for Kerendia as it will allow generic manufacturers to produce and market cheaper versions of the medication. This will likely lead to increased competition and reduced costs for patients. According to DrugPatentWatch.com, the patent for Kerendia was filed in 2016 and granted in 2019, with a patent expiration date set for 2036 [2].

Timeline for Patent Expiration

To determine the exact date of patent expiration, we need to consider the patent's expiration date and any potential patent term extensions (PTEs) that may have been granted. As of now, the patent expiration date is set for 2036. However, it's essential to note that patent laws can change, and PTEs may be granted, which could extend the patent's lifespan.

What Happens Next After Kerendia's Patent Expiration?

Following patent expiration, generic manufacturers will be able to produce kerendia, which will enter the market. This will likely lead to increased competition, reduced prices, and greater accessibility for patients. The introduction of generic kerendia will also create opportunities for the development of biosimilars, which will compete directly with the original product.

References

[1] Kerendia (finerenone) for Diabetic Nephropathy. Drugs.com.

[2] Finerenone (Bayer; Janssen Pharmaceuticals). DrugPatentWatch.com.